Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma

Table 2 Genetic polymorphisms in DNA repair genes and survival of patients

Genotype	Patients(%)	MST(mon)	Log-rank P	HR(95%CI)	Adjusted HR(95%CI)^A
ERCC2 Lys751Gln
AA	194(75.5)	14.50		1.00	1.00
AC	59(23.0)	10.40	0.10	1.40(1.01-1.94)	1.32(0.95-1.84)
CC	4(1.5)	12.27		0.73(0.23-2.28)	0.79(0.25-2.48)
AC/CC^B	63(24.5)	10.97	0.08	1.33(0.97-1.82)	1.27(0.92-1.75)
ERCC2 Asp312Asn
GG	229(89.1)	13.23		1.00	1.00
GA	27(10.5)	12.40	0.05	0.95(0.60-1.49)	0.95(0.60-1.49)
AA	1(0.4)	4.40		8.25(1.12-60.60)	8.55(1.14-64.25)
GA/AA^C	28(10.9)	9.83	0.96	0.99(0.63-1.54)	0.99(0.63-1.54)
ERCC1 Asn118Asn
CC	140(54.5)	17.23		1.00	1.00
CT	94(36.6)	11.07	< 0.001	1.58(1.18-2.12)	1.48(1.10-1.99)
TT	23(8.9)	6.20		2.82(1.72-4.62)	2.67(1.62-4.40)
XRCC1 Arg399Gln
GG	117(45.5)	19.10		1.00	1.00
GA	102(39.7)	10.40	< 0.001	1.41(1.05-1.91)	1.28(0.95-1.74)
AA	38(14.8)	9.23		2.33(1.56-3.47)	2.68(1.79-4.02)

Abbreviation: MST, median survival time; HR, hazard ratio; CI, confidence interval.
^AHR adjusted for age, stage, surgical operation and chemotherapy or radiotherapy.
^BLog-rank P and HR were calculated compared with wild genotype(AA) of ERCC2 751 polymorphism.
^CLog-rank P and HR were calculated compared with wild genotype(GG) of ERCC2 312 polymorphism.

ISSN: 1471-2407